Literature DB >> 17111242

Extreme thrombocytosis under the treatment by amoxicillin/clavulanate.

Chih-Jen Yang1, Jhi-Jhu Hwang, Jen-Yu Hung, Inn-Wen Chong, Ming-Shyan Huang.   

Abstract

Amoxicillin/Clavulanate related extreme thrombocytosis during the treatment of pneumonia has never been reported. We present a 54-year-old patient who was admitted due to pneumonia, and was treated with amoxicillin/clavulanate IV and 3-day course of 500 mg azithromycin. Despite clinical and radiological evidence showing that pneumonia improved, thrombocytes increased rapidly. After stopping the antibiotic, the thrombocytes returned gradually to normal. Considering the clinical course, we propose that this extreme thrombocytosis was caused by the administration of amoxicillin/clavulanate. We describe this rare and unique patient and review the literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17111242     DOI: 10.1007/s11096-006-9051-5

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  9 in total

1.  Thrombocytosis and hyperkalemia associated with the use of ticarcillin/clavulanic acid.

Authors:  S B Moody; K S Pawlicki
Journal:  Drug Intell Clin Pharm       Date:  1987-03

Review 2.  Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.

Authors:  M A Elliott; A Tefferi
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

3.  Ticarcillin/clavulanic acid combination. Treatment of bacterial infections in hospitalized children.

Authors:  K Kristjansson; F Cox; L Taylor
Journal:  Clin Pediatr (Phila)       Date:  1989-11       Impact factor: 1.168

4.  Extreme thrombocytosis: what are the etiologies?

Authors:  Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2006-01       Impact factor: 2.389

5.  Thrombocytosis during antifungal therapy of candidemia.

Authors:  Angela D Saathoff; Stephanie L Elkins; Stanley W Chapman; Susan Fleming McAllister; John D Cleary
Journal:  Ann Pharmacother       Date:  2005-05-24       Impact factor: 3.154

6.  The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.

Authors:  D H Buss; J J Stuart; G E Lipscomb
Journal:  Am J Hematol       Date:  1985-12       Impact factor: 10.047

7.  Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases.

Authors:  D H Buss; A W Cashell; M L O'Connor; F Richards; L D Case
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

8.  Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.

Authors:  Josef Finsterer; Nicole Kotzailias
Journal:  Platelets       Date:  2003-08       Impact factor: 3.862

Review 9.  Drug-induced thrombocytosis.

Authors:  J L Frye; D F Thompson
Journal:  J Clin Pharm Ther       Date:  1993-02       Impact factor: 2.512

  9 in total
  3 in total

1.  A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis.

Authors:  Nagehan Aslan; Dincer Yildizdas; Yasemin Coban; Ozden Ozgur Horoz; Gulen Gul Mert; Neslihan Ozcan
Journal:  Indian J Pediatr       Date:  2019-09-13       Impact factor: 1.967

Review 2.  Thrombocytosis in the NICU.

Authors:  David J Powner; W Keith Hoots
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 3.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.